Coronavirus Vaccine Update: Sinopharma, Gamalei make progress
Coronavirus Vaccine Update: Some of the biggest pharmaceutical and medical research institutions around the world are working overtime to develop a vaccine for Coronavirus. As per the latest reports, more than 165 vaccines are under development, at various stages of approval. 135 vaccines are have not yet reached human trials, 18 have reached phase one of the limited human trial while 6 vaccines are at the promising third phase of development.
Let’s take a deeper look at the different vaccines that are at play here.
In a positive development, a vaccine developed by Russian Gamalei Research Institute and the Russian Defence Ministry is set to be registered next week, on the 12th of August. Clinical trials of this vaccine started in June and it was tested on 76 volunteers. Initial reports showed no side effects or any other issues with the body of the volunteers were found and “unmistakable immune response attained through the vaccination.” As per Sputnik News.
In the Emirates, Sinopharma’s Phase III testing is showing great results. The results of this trial – in which more than 5,000 volunteers have participated – are showing the success of this procedure. The third phase of the trial, which began in the Gulf nation’s capital on 16 July Among the more than 5,000 volunteers who have already received the vaccine from the Emirates are people of different ages, ranging from 18 to 60
Vaccine frontrunners Moderna which in partnership with the National Institutes of Health were the first to test their vaccine on humans back in March has enrolled a final trial phase. They are enrolling about 30,000 healthy people at about 89 different sites around the United States of America. They have strong support from the government as well who has provided them with a $1 billion funding.
One of the most talked-about Coronavirus vaccine research – The University of Oxford research, is now in Phase one and phase two trials in England and India, whereas in Brazil and South Africa they have reached phase 3. This research is in collaboration with a British-Swedish AstraZeneca. They have had one of the most positive results and are in a position to deliver emergency vaccines by October. The Serum Institute of India has already produced millions of doses that are ready to be used in trials.
German company BioNTech in collaboration with Chinese drug maker Forum Pharma and New York based Pfizer has entered the vaccine race and are developing an mRNA vaccine. Phase three of the trials started in the last week of July and they found that the volunteers produced antibodies against SARS-CoV-2, as well as immune cells called T cells that respond to the virus. While in case of side effects some experienced moderate side effects that included sleep disturbances and sore arms. The company is confident of delivering almost 1.3 billion doses by the end of 2021 if the vaccine gets approved.
India’s Bharat Biotech collaborated with the National Institute of Virology to develop a vaccine, Covaxin and also stared human trials in the last week July. They have completed their first phase of human trials in a quick three week period and are planning to proceed ahead with phase two human trials.
Another Indian candidate for the development of the coronavirus vaccine is Zydus Cadila. Zydus Cadila is working on a DNA based vaccine and has already progressed to phase 2 of trials. Considering we are in unprecedented times, the drugmaker had received approval from drug controller general of India (DCGI) V.G. Somani for conducting simultaneous phase I and II trials without compromising on the safety and the efficacy of the trials.
French company Sanofi in partnership with Translate Bio has also started developing an mRNA based vaccine for the Coronavirus. They’re not at a very advance stage but have already started with Phase one of the trials.
Chinese researchers at the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Walvax Biotechnology that have data on vaccines that have shown protective effects on monkeys have said they’ll enter the country’s first safety trials on an mRNA-based vaccine, called ARCoV. 3. Another UK based research is showing some positive results, the researchers at the Imperial College London have developed a vaccine which boosts the production of viral protein that stimulated the immune system. They are already at phase one and phase two of the testing and expect the vaccine to be ready by the end of the year
With the world at a standstill because of the pandemic, everyone is looking up to the medical community to come up with a vaccine that’ll rid us of this deadly virus and help life resume to normal and not the new-normal.